Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) has received a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $31.3333.
BDSX has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their price target on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Finally, Roth Capital began coverage on shares of Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 target price for the company.
View Our Latest Research Report on BDSX
Insider Transactions at Biodesix
Institutional Trading of Biodesix
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd increased its holdings in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Biodesix in the 4th quarter valued at $68,000. DRW Securities LLC acquired a new stake in shares of Biodesix during the 4th quarter valued at $105,000. Allworth Financial LP acquired a new stake in shares of Biodesix during the 2nd quarter valued at $112,000. Finally, Millennium Management LLC bought a new stake in Biodesix during the 3rd quarter worth $113,000. Institutional investors own 20.96% of the company’s stock.
Biodesix Price Performance
BDSX stock opened at $24.22 on Thursday. The company’s 50-day moving average price is $20.19 and its two-hundred day moving average price is $16.05. The firm has a market cap of $255.52 million, a P/E ratio of -7.64 and a beta of 0.56. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix has a 12 month low of $5.26 and a 12 month high of $25.52.
Biodesix (NASDAQ:BDSX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. The company had revenue of $26.86 million during the quarter, compared to the consensus estimate of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. On average, analysts anticipate that Biodesix will post -2.68 earnings per share for the current fiscal year.
Biodesix Company Profile
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Featured Stories
- Five stocks we like better than Biodesix
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
